Coagulation Profile of a Common Statin Identified

Rosuvastatin, 20 mg/day, can improve the coagulation profile of patients with venous thrombosis (VT), according to results of a new study.

For their study, the researchers performed a randomized clinical trial of rosuvastatin, 20 mg/d, for 4 weeks. Overall, 247 participants with unprovoked VT were randomly assigned to rosuvastatin or no intervention.

__________________________________________________________________________________

RELATED CONTENT
CKD Severity Influences Post-TAVR Outcomes
Heart and Mind: TAVR Outcomes Linked to Depression
__________________________________________________________________________________

Participants had received a blood test at baseline and after 28 days of intervention.

The 5 primary coagulation factors measured included FVIII:C, von Willebrand factor:Ag, FVII:C, FXI:C, and D-dimer.

After analyzing the data, the researchers found the mean levels of coagulation factors had been reduced among participants who had taken rosuvastatin, but levels remained unchanged in participants not taking statins.

Among rosuvastatin users, mean FVIII:C levels were 7.2 IU/dL lower, but no change was seen among non-users.

Additional analyses showed an even more pronounced reduction in coagulation factors in participants with unprovoked VT and in those with cardiovascular risk factors.

“Rosuvastatin 20 mg/day substantially improved the coagulation profile among patients with prior VT,” the researchers concluded. “These results suggest that statin therapy might be beneficial in patients at risk of recurrent VT.”

—Amanda Balbi

Reference:

Biederman JS, Kruip MJHA, van der Meer FJ, et al. Rosuvastatin use improves measures of coagulation in patients with venous thrombosis [published online January 30, 2018]. Eur Heart J. https://doi.org/10.1093/eurheartj/ehy014.